Protagonist Therapeutics(NASDAQ) PTGX

Protagonist Therapeutics develops new medicines using a special technology to create small, stable molecules called peptides. These treatments help people with rare blood disorders, painful skin conditions, and obesity. The company creates drugs that can be taken as pills or shots to improve daily life.

What is Protagonist Building?

• Rusfertide: Injectable treatment for polycythemia vera, a rare blood disorder causing excess red blood cells; submitted for FDA approval in December 2025.
• Icotrokinra: Oral peptide blocking the IL-23 receptor for moderate-to-severe plaque psoriasis; applications for approval were submitted to regulators in 2025.
• PN-881: Oral therapy for immune-mediated skin diseases like psoriasis; targets the IL-17 pathway and entered first human trials in late 2025.
• Obesity Pipeline: New drug candidates PN-477 and PN-458 designed as oral and injectable options for weight management; both nominated for development in 2025.
• PN-8047: Oral small molecule designed to mimic the hormone hepcidin to help manage iron levels in patients with blood disorders.

Key Moves and Partnerships

• Entered a licensing and collaboration agreement with Takeda Pharmaceuticals USA, Inc. in January 2024 to develop and sell rusfertide.
• Partnered with Janssen Biotech, Inc., a Johnson & Johnson company, to advance icotrokinra through global regulatory submissions in 2025.
• Maintains a research agreement with Zealand Pharma A/S to identify and optimize new peptide-based medicines for specific biological targets.
• Nominated two new development candidates for obesity treatment, PN-477 and PN-458, in June and December 2025 respectively.

What Makes the Platform Unique?

The company uses a proprietary platform to build constrained peptides that combine the high potency of large injectable drugs with the convenience of small pills. This approach targets complex biological pathways that are often difficult for traditional medicines to reach effectively.

The Recent Financial Picture

• Total revenue fell to $7.4 million in Q4 2025, down 95.6% from $170.6 million in Q4 2024.
• Net income dropped to a loss of $44.4 million in Q4 2025, down 133.7% year-over-year.
• Cash and marketable securities grew to $646 million by December 31, 2025, up from $559.2 million in 2024.
• Market capitalization rose to $5.6 billion in Q4 2025, a 130.8% increase from $2.4 billion in Q4 2024.

Bottom Line

Protagonist has transitioned from a research-focused firm to a development company with two major products awaiting regulatory decisions. By partnering with global pharmaceutical leaders, the company is preparing to move its peptide technology into large-scale commercial markets.